作者的详细信息

Гречухина, Катерина Сергеевна

期 栏目 标题 文件
卷 21, 编号 3 (2019) Articles Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population PDF
(Rus)
卷 24, 编号 1 (2022) CLINICAL ONCOLOGY NGAL and KIM-1 – early urinary biomarkers of nephrotoxicity mediated by cisplatin: Observational study PDF
(Rus)
卷 24, 编号 3 (2022) CLINICAL ONCOLOGY Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report PDF
(Rus)
卷 25, 编号 1 (2023) CLINICAL ONCOLOGY The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review PDF
(Rus)
卷 26, 编号 2 (2024) Articles Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review PDF
(Rus)
卷 26, 编号 1 (2024) Articles Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study PDF
(Rus)
卷 27, 编号 1 (2025) Articles Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review PDF
(Rus)